Q2052 – Services, supplies and accessories used in the home for the administration of intravenous immune globulin (ivig)

Long description

Services, supplies and accessories used in the home for the administration of intravenous immune globulin (ivig)

Short description

Home ivig, services/supplies

Pricing indicator

57 Other carrier priced

Medicare coverage

D Special coverage instructions apply

BETOS category

O1E Other drugs

Added

April 1, 2014

Last change

July 1, 2023 – No change

Nearby Q codes

• Q2038 – Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluzone)
• Q2039 – Influenza virus vaccine, not otherwise specified
• Q2040 – Tisagenlecleucel, up to 250 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per infusion
• Q2041 – Axicabtagene ciloleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
• Q2042 – Tisagenlecleucel, up to 600 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
• Q2043 – Sipuleucel-t, minimum of 50 million autologous cd54+ cells activated with pap-gm-csf, including leukapheresis and all other preparatory procedures, per infusion
• Q2049 – Injection, doxorubicin hydrochloride, liposomal, imported lipodox, 10 mg
• Q2050 – Injection, doxorubicin hydrochloride, liposomal, not otherwise specified, 10 mg
• Q2053 – Brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
• Q2054 – Lisocabtagene maraleucel, up to 110 million autologous anti-cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
• Q2055 – Idecabtagene vicleucel, up to 510 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
• Q2056 – Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
• Q2057 – Afamitresgene autoleucel, including leukapheresis and dose preparation procedures, per therapeutic dose
• Q2058 – Obecabtagene autoleucel, 10 up to 400 million cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per infusion
• Q3001 – Radioelements for brachytherapy, any type, each
• Q3014 – Telehealth originating site facility fee